Follow us:

Anesthesia-Intensive care and Pain Therapy (AICPT)

Research

Lidocaine for Spinal Anesthesia. Can and should be used.

Corresponding Author:Luiz Eduardo Imbelloni*,Anesthesiologist of Complexo Hospital Mangabeira, João Pessoa, PB-Brazil, email: dr.imbelloni@hotmail.com

Article Information

Article Type: Research

Received : September 27, 2018
Accepted : October 09, 2018
Published: October 12, 2018

Abstract

Lidocaine was introduced as a local analgesic in 1949. It has been proven to be very successful as a regional anesthesia. Although experimental animal studies have provided evidence that some local anesthetics in clinical concentration could cause damage to the nerve tissue, the exact mechanism of the lesion is not clearly defined. Laboratory data indicate the potential for lidocaine neurotoxicity and a concentration dependence of local anesthetic neurotoxicity.
Lidocaine administered intrathecally for spinal anesthesia, on the one hand, is considered by many the prototypical drug for spinals, especially for same-day surgery and short-stay procedures. Several solutions of lidocaine can be used: 1.5% and 2% hyperbaric, 2% isobaric and 0.6% hypobaric. All solutions with applicability in daily clinical practice and shown in this article.

Key words: Anesthetic techniques: spinal; Local anesthetic: lidocaine

 

Article

Introduction

In a recent e-book "Lidocaine: Current Concepts and Emerging Roles in Clinical Practice," a chapter was written on the use of lidocaine for spinal anesthesia[1].Spinal anesthesia has been used now for over a century, and a number of local anesthetics are available. Increased employment of day case surgery has led to increased use of spinal anesthesia, especially with rapid onset and short duration of action, allowing patients to go home sooner.
Lidocaine, the first amino amide type local anesthetic, was first synthesized under the namexylocaine by Swedish chemist Nils Lofgren in 1943. His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself [2]. It was first marketed in 1949.The drug was a result of a series of experiments with basic anilids which were widely different in structure from the cocaine-procaine group.  Many of the advantages of lidocaine over procaine are due to the substitution of the ester linkage in the long side chain by an amide group, but the presence of the two ortho-methyl groups is also vital. The use oflidocainefor spinal anesthesia wasfirst published in1948 witha 2 mL of 2% solutionin10% glucose for urological operations produced arapidand satisfactoryanesthesia [3]. In 1954 Berne reported his experience with the 5% solution [4]. In the late1950smanypapers werepublished describing the use of 5%lidocaine. In 1956, a study comparing the efficacy of 5% lidocainein 7.5%dextrosewith 2.5% lidocainein 4% dextroseshowed that the most effective spinal anesthesia was obtainedwith1.5mLof the 5% solution [5]. The reason for using 5% lidocaine for spinal anaesthesia is unclear and this concentration has been repeatedly linked to a transient radicular irritation syndrome, particularly in hyperbaric preparations. In Brazil the solutions used in spinal anesthesia are: 2% isobaric lidocaine [6], 1.5% and 2% hyperbaric lidocaine [7] and 0.6% hypobaric lidocaine [8].

Medotological Evaluation Errors

Lidocainewas synthesizedin 1943andintroduced as a 2% hyperbaricpreparationfor use inspinal anaesthesia. It became popularforshort durationproceduresdue to rapidregression of the sensory and motor block, which enhanced itssafety.  For almost 50 years, lidocaine has enjoyed an incredible popularity as a short-acting local anesthetic and was considered to represent a standard drug for short surgical procedures performed under spinal anesthesia. Its reputation was based on a remarkable safety record devoid of reports suggesting a potential for neurotoxicity and the results from a large-scale prospective review [9]. Since then, according to reasonable estimates, lidocaine has been used effectively and safely for spinal anesthesia in some fifty million patients [10]. This preparation wasused safely for a longperiod untilthe onset ofcauda equine syndromewithuse ofmicrocathetersforcontinuousspinal anesthesia [11].

Although spinal anesthesia is associated with relatively low rates of neurological complications, when complications do occur the effects may be severe and permanent. These may be a result of a combination of needle injury, unusual anatomy, and the effect of anesthetic drugs.  

Cauda equina syndrome (CES) is a serious neurologic condition in which there is acute loss of function of the lumbar plexus, neurologic elements (nerve roots) of the spinal canal below the termination (conus medullaris) of the spinal cord.

In 1991, four cases of persistent sacral nerve root deficits were reported following continuous spinal anesthesia [11] (Table 1). In all cases, a dose of local anesthetic had been administered that by far exceeded recommended dosages for single-shot spinal anesthesia; in 3 cases, 5% lidocaine had been injected through a 28-G microcatheter, whereas in the remaining case 0.5% tetracaine was administered through a 20-G catheter (epidural catheter). Similar reports soon followed and finally led to an alert aboutits usein spinal microcatheters from the US market [12, 13]. As a possible mechanism, it was suggested that the slow speed of injection when using spinal microcatheters results in poor mixing of the local anesthetic with the cerebrospinal fluid and consequent maldistribution, thus exposing neural tissue to potentially toxic concentrations of local anesthetic [14-16].

In the four cases reported in 1991 [11], three were with 5% lidocaine injected through the microcatheter and one case with tetracaine 0.5% injected through the 20G catheter (epidural catheter). In this way, lidocaine and microcatheter could never be incriminated, because tetracaine and a large caliber catheter were involved in these cases. What led the FDA [12] to make an alert unfortunately is not understandable. Paracelsus, physician and physicist of the sixteenth century, said “all things are poison and nothing is without poison, only the dose permits something not to be poisonous”.

Six cases of cauda equina syndrome with varying severity were reported to Swedish Pharmaceutical Insurance during the period 1993-1997 [17] (Table 2). All were associated with spinal anesthesia using hyperbaric 5% lidocaine. Five cases had single-shot spinal anaesthesia and one had a repeat spinal anesthetic due to inadequate block. The dose of hyperbaric 5% lidocaine administered ranged from 60 to 120 mg.  Clearly, as the authors so appropriately underscore, the diagnosis of direct local anesthetic neurotoxicity is one of exclusion. Care must be exercised to rule out trauma; spinal cord ischemia; infection; compression by hematoma, abscess, prolapsed intervertebral disc and spondylolisthesis; contamination of local anesthetics; and injurious surgical positioning. The authors considered that three of the cases were most probably the result of direct neurotoxicity of 5% hyperbaric lidocaine. Furthermore, in the other three cases, direct neurotoxicity was also probable, but a compressive etiology could not be excluded owing to the omission of appropriate radiological studies. These six cases were reported by reported to the Swedish Pharmaceutical Insurance; however it is clear that the anesthesia sheets were not adequately filled, since 50% of the cases there is no report of the caliber or type of needle.

We have been using a macro spinal catheter system for continuous spinal anesthesia in obstetric analgesia [18]. It is a 24-gauge catheter mounted over a 29-gauge spinal needle (Spinocath®). The design eliminates leakage of CSF because the catheter seals the dural puncture hole. A recently publishedcase reportdescribed the use ofhigh dosesof two local anestheticswithcontinuous spinal anesthesia [19](Table 3). The use of two anesthetics was justified by the long duration of the surgery and, after the programmed dose of bupivacaine, lidocaine was the drug chosen to avoid possible residual motor blockade in high-risk patients. With the administration of high doses of hyperbaric anesthetics through the new catheter (Spinocath®), maldistribution of local anesthetic and cauda equina syndrome were not observed [19].

The cauda equina syndrome was correlated to the use of continuous spinal anesthesia with a microcatheter and high doses of local anesthetics [11,14] leading to a reduction in the use of this technique. The poor distribution of the local anesthetic, which remained confined to the sacral region, was one of the mechanisms blamed for this syndrome [14, 15]. Laboratorial analysis [14] showed that the low speed of injection of the microcatheter attributed to its small diameter was responsible for the poor distribution of the local anesthetic, with accumulation of toxic concentration on the roots of the cauda equina. In this study, an incomplete motor blockade and insufficient sensorial level was observed, but it was possible to complete the dose of bupivacaine, necessary for analgesia of the upper abdomen, and lidocaine to maintain analgesia of the lower abdomen to complete the procedure. The head-down position prevented sequestration of the solution at the dural cul-de-sac, therefore protecting the sacral roots.

Neurotoxicity of Lidocaine

In the initial study of lidocaine, the authors used the pure solution at concentrations of 0.5% and 2%, and with the addition of epinephrine at concentrations of 0.5%, 1% and 2% [3]. In an excellent Editorial [20], the potency ratio of lidocaine versus bupivacaine is approximately 4:1, and 5% lidocaine should be compared with 1.25% bupivacaine and not 0.5 or 0.75% bupivacaine. Or rather, bupivacaine 0.5% should be compared to lidocaine 2% and not 5%. Are there any reports on permanent neurologic damage after single shot uneventful spinal anesthesia with lidocaine 2%? And the author ends his sentence by saying that he is not aware of any. 

A study published recently in dogs on increasing doses of hyperbaric lidocaine (5%, 7.5%, and 10%, all in glucose 7.5% in water) demonstrated that the 5% lidocaine concentration is safe to be used in subarachnoid anesthesia and that concentrations higher than 7.5% lead to histological changes in the spinal cord but not in the meninges [21].

As a component of anesthetic solution, glucose was usually used to increase the density of anesthetic solution, which can be great benefit to cycle fluctuations inhibition in clinical anesthesia. Hyperbaric local anesthetics made with glucose produce effectiveness in controlling the level of anesthesia. With its different proportion in mixture, glucose of various concentrations that act as a common component in anesthetic solution is being used for spinal anesthesia. Intrathecal injection of 5% lidocaine could induce spinal nerve sensory impairment, and 10% glucose could worsen the potential neurotoxicity of rats with intrathecal administration of 5% lidocaine [22]. The study suggests that the potential neurotoxicity should be considered when the local anesthetics mixed into high concentration of glucose are used in subarachnoid block.

Articles with Lidocaine Published in the Last Decade

Lidocaine has been used for spinal anesthesia since 1948, seemingly without causing concern. Hip fractures are considered as age related diseases. Spinal anesthesia has become increasingly popular in the setting of hip and knee arthroplasty.It was confirmed that general anesthesia with sevoflurane and spinal anesthesia with low dose lidocaine 5% (75 mg) have comparable effects on hemodynamic changes in patients undergoing hip fracture surgery [23]. However, postoperative vomiting and morphine consumption in patients with spinal anesthesia was lower than general anesthesia [23]. Isobaric lidocaine spinal anesthesia appears to be a safe andeffective regimen for same-day ambulation, short-stay TJA, and evenoutpatient hip and knee arthroplasty [24].  In this prospective small cohortof consecutive patients, all patients were discharged on the day ofsurgery with rapid return of motor function and time to ambulation.There were no reports of TNS.

In a recent study evaluating three different doses of isobaric 2% lidocaine for ventral decubitus surgery, it showed that may have several advantages, especially for outpatient procedures, such as fast recovery, hemodynamic stability, patient satisfaction, with more sensitive than motor block in the lower limbs, fast recovery, no urinary retention, and increased risk for temporary neurological symptoms. In addition, the patient is already anesthetized in the position in which he will be operated (ventral decubitus) [25].

Foot surgeries can be performed with the patient in a position of dorsal decubitus, lateral position or ventral decubitus. Comparing 2% isobaric lidocaine (50 mg) with 0.6% hypobaric lidocaine (24 mg) in the Jack-Knife position provide surgical analgesia with complete block with isobaric lidocaine and without motor block with hypobaric lidocaine for foot surgery. Most importantly, it allowed the patient to remain in this position, providing for better surgical exposure for surgeon and patient safety. In our study, with hypobaric lidocaine all patients went from the operating table to the stretcher without help, and better degree of satisfaction [26].

Studying the incidence of TNS with different local isobaric anesthetic, showed that the incidence of TNS after spinal anesthesia was much less after levobupivacaine,

bupivacaine and articaine than after lidocaine; however it appears that TNS may occur in association with levobupivacaine and articaine [27].

Lidocaine Can and should be used

Lidocaine was approved by the Food and Drug Administration (FDA) in 1948 and in time became the local anesthetic typically used when quick onset and regression of spinal anesthesia were desired. A single injection is appropriate for a 1 to 2 hour surgery, whereas multiple injections through a spinal catheter allow for longer surgery time while maintaining a rapid recovery profile. Lidocaine spinal anesthesia facilitates discharge of surgical outpatients within a few hours while decreasing recovery room time and nursing costs for surgical inpatients [28].Besides the convenience to patients, this also has considerable implications for decreasing the cost of health care.

Several case reports of cauda equina syndrome were attributed to the use of the hyperbaric solution (lidocaine and tetracaine) injected through a microcatheter and epidural catheter. Followingthesereportswithcontinuousspinalanesthesia, single-dose spinal anesthesia with 5% hyperbaric lidocaine was linked with TNS. Studies examining the use of lidocaine have caused many anesthetists to question whether intrathecal lidocaine should still be used.

The firstreview of the useof lidocainespinal anesthesiaand its association withneurological complications was published in 1969[9]. This study involved 10,440 patients who received 5% hyperbaric lidocaine, and the dose ranged from 40 to100 mg,with nopatient receivingmore than 100mg. In this series, there were no cases of cauda equina syndrome. TNS shows no evidence for localized nerve damage. The implication is that TNS is ‘no big deal’ [29].

The ideal local analgesic drug should combine quick action, complete abolition of painful sensation, adequate duration of analgesia, low toxicity, ready diffusability and stability when in solution, with a low incidence of local and general side effects and it should also be an efficient surface as well as an injection agent. Lidocaine remains a popular choice for ambulatory spinal anesthesia. It provides rapid onset of surgical anesthesia for the majority of ambulatory surgical procedures along with a rapid regression of sensory and motor blockade. It appears that total dose of lidocaine, but neither concentration nor volume, is the most important factor in determining both peak level and duration of spinal anesthesia [30]. 

Conclusion

It is my opinion that a short-acting alternative to bupivacaine for spinal anesthesia is needed. To date, there have been no anesthetics with the characteristics of lidocaine for surgeries lasting 60 to 90 minutes. If a short-acting spinal is indicated, use 2% lidocaine and reduce the total dose to a maximum of 60–80 mg. We should not throw out ‘‘an old champion’’ unjustified [20]. There is still no proof that lidocaine toxicity is the explanation of these phenomena. Lidocaine for spinal anesthesia has a remarkable safety record, and in this way it can and should be used in spinal anesthesia.

 

References

1.   Imbelloni LE. (2014) Lidocaine for spinal anesthesia. IN: Karen Stuart-Smith, Editor"Lidocaine: Current Concepts and
      Emerging Roles in Clinical Practice", Nova Science PublishersInc, Chapter 1, pg 1-19. 
2.   Löfgren N, Lundqvist B. (1946) Studies on local anaesthetics II. Svensk Kemisk Tidskrift,58: 206-217.
3.   Gordh T. Xylocain.  (1949) A new local analgesic. Anaesthesia, 4: 4-9.
4.   Berne S. (1954) Spinalanestesi med xylocaine Tung 5%. Svensk Lakartidn, 51: 1037-1041.
5.   Adams BW.  (1956) Lignocaine spinal analgesia in transurethral prostatectomy. Anaesthesia, 11: 297-302.
6.   Imbelloni LE, Carneiro ANG. (1998) Effect of posture on the spread of plain 2% lidocaine. Rev Bras Anestesiol, 48: 1-6.
7.   Imbelloni LE, Carneiro ANG. (1999) Comparison of 1.5% and 2% lidocaine with dextrose for spinal anesthesia.
      Rev Bras Anestesiol,49: 9-13.
8.   Imbelloni LE, Gouveia MA, Vieira EM, Cordeiro JA. (2008)Selective sensory spinal anaesthesia with hypobaric lidocaine
      for anorectal surgery. Acta Anaesthesiol Scand, 52: 1327-30.
9.   Phillips OC, Ebner H, Nelson AT, Black MH. (1969) Neurologic complications following spinal anesthesia with lidocaine:
      a prospective review of 10440 cases. Anesthesiology, 30: 284-9.
10. Renck H. (1995) Neurological complications of central nerve blocks. Acta Anaesthesiol Scand, 39: 859-68.
11. Rigler ML, Drasner K, Krejcie TC, Yelich SJ, Scholnick FT, et al.(1991) Cauda equina syndrome after continuous spinal
      anesthesia. Anesth Analg, 72: 275-81.
12. Schell RM, Brauer FS, Cole DS, (1991) Applegate RRLI. Persistent sacral nerve root deficits after continuous spinal
      anaesthesia. Can J Anaesth,38: 908-11.
13. FDA Safety Alert. Cauda equina syndrome associated with the use of small-bore catheters in continuous spinal
      anesthesia. May 1992.
14. Rigler ML, Drasner K. (1991) Distribution of catheter-injected local anesthetic in a model of the subarachnoid space.
      Anesthesiology, 75: 684-92.
15. Ross BK, Coda B, Heath CH. (1992) Local anesthetic distribution in a spinal model: a possible mechanism of neurologic
      injury after continuous spinal anesthesia. Reg Anesth, 17: 69-77.
16. Robinson RA, Stewart SF, Myers MR, Lien LF, Rinaldi JR, et al.(1994) In vitro modeling of spinal anesthesia. A digital video
      image processing technique and its application to catheter characterization. Anesthesiology, 81: 1053-60.
17. Loo CC, Irestedt L. (1999) Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: A review of six
      cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.
      Acta Anaesthesiol Scand, 43: 371-379.
18. Imbelloni LE, Gouveia MA. (2006) Continuous spinal anesthesia with Spinocath® for obstetric analgesia.
      Int J Obstetric Anesth, 15: 172.
19. Imbelloni LE, Gasparini Neto S, Ganem EM. (2010) Continuous spinal anesthesia with high dose of local anesthetics.
      Rev Bras Anestesiol, 60: 537-43.
20. Gisvold SE. (1999) Lidocaine may still be an excellent drug for spinalanaesthesia. (Editorial).
      Acta Anaesthesiol Scand, 43: 369-370.
21. Pires SRO, Ganem EM, Marques M, (2006) Effects of increasing spinal hyperbaric lidocaine concentrations on spinal cord and
      meninges. Experimental in dogs. Rev Bras Anestesiol, 56:253-262.
22. Ma H, Xu T, Xiong X, Mao J, Yang F, et al.(2015) Effects of glucose administered with lidocaine solution on spinal neurotoxicity
      in rats. Int J Clin Exp Med; 8: 20638-20644.
23. Haghighi M, Sedighinejad A, Nabi BN, Mardani-Kivi M, Tehran SG, MD; et al.(2017) Is spinal anesthesia with low dose lidocaine
      better than sevoflorane anesthesia in patients undergoing hip fracture surgery. Arch Bone Jt Surg, 5(4): 226-30. 
24. Frisch NB, Darrith B, Hansen DC, Wells a, Sanders S, et al.(2018) Single-dose lidocaine spinal anesthesia in hip and knee
      arthroplasty. Arthroplasty Today, xxx: 1-4.
25. Imbelloni LE, Carvalho SM, Anjos D. Camacho L, Morais Filho GB. (2018) Lidocaine 2% pure for orthopedic calcaneal surgeryin
     decubitus ventral. Study with different doses. J Clin Anesth Pain Med,; 2 (2): 019.
26. Imbelloni LE, Sales MBL, Ventura TB, Camacho L, Morais Filho GB. (2018) Lidocaine for dorsal spinal anesthesia for ambulatory
      orthopedic foot surgery. A comparative study between isobaric and hypobaric solutions. World J Pharm Pharm Scien, 7 (8): 139-149.
27. Gozdemir M, Muslu B, Sert H, Usta B, Demiroglu RI, et al. (2016) Transient neurological symptoms after spinal anesthesia.
      Clin Invest Med, 39 (6): S106-S110. 
28. Frey K, Holman S, Mikat-Stevens M, Vazquez J, White L, et al.(1998) The recovery profile of hyperbaric spinal anesthesia with
      lidocaine, tetracaine, and bupivacaine. Reg Anesth Pain Med,23: 159-63.
29. Lambert DH. (2006) is TNS really no big deal? Anesth Analg,102: 654.
30. van Zundert AAJ, Grouls RJE, Korsten HMM, Lambert DH. (1996) Spinal anesthesia: volume or concentration.
      What matters? Reg Anesth, 21: 112-8.

 

Address
  • 27 Old Gloucester street,
    London United kindom,WCIN3AX.
Contact Us
License
Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.
© 2018. Vagus Inprosys All right reserved.